CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 
 

LGVN's Net Income Growth by Quarter and Year

Longeveron Inc 's Net Income results by quarter and year




LGVN Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 9.87 0.00 0.00
III Quarter September - -4.86 0.00 0.00
II Quarter June -5.62 -5.01 0.00 0.00
I Quarter March -3.51 0.00 0.00 0.00
FY   -9.13 0.00 0.00 0.00



LGVN Net Income second quarter 2022 Y/Y Growth Comment
Longeveron Inc in the second quarter 2022 recorded net loss of $ -5.62 millions.

According to the results reported in the second quarter 2022, Longeveron Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Longeveron Inc ' s Net Income no change of % ranks overall at the positon no. in the second quarter 2022.




LGVN Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Longeveron Inc 's second quarter 2022 Net Income $ -5.62 millions LGVN's Income Statement
Longeveron Inc 's second quarter 2021 Net Income $ -5.01 millions Quarterly LGVN's Income Statement
New: More LGVN's historic Net Income Growth >>


LGVN Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Longeveron Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LGVN's II. Quarter Q/Q Net Income Comment
Recent results of -5.62 millions by Longeveron Inc appear even less good if you take a look at -3.51 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Longeveron Inc achieved highest sequential Net Income growth. While Longeveron Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LGVN's II. Quarter Q/Q Net Income Comment
Current results of -5.62 millions by Longeveron Inc look even worse compare to the -3.51 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Longeveron Inc achieved highest sequential Net Income growth. While Longeveron Inc 's Net Income growth quarter on quarter, overall rank is .


Longeveron Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Net Income 12 Months Ending $ -4.12 $ -4.12 $ -3.51 $ 0.00 $ 0.00
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Longeveron Inc ' has realized cumulative trailing twelve months net loss of $ -4 millions in the Sep 30 2022 period.
The results are detiriorating as the cumulative net loss is inflating from $ -3.51 millions in TTM ending quarter Jun 30 2022 and $ -3.51 millions for the twelve months ending in the quarter Sep 30 2021.

Longeveron Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Longeveron Inc ' has realized cumulative trailing twelve months net loss of $ -4 millions in the Sep 30 2022 period.
The situation is worsening as the cumulative net loss is inflating from $ -3.51 millions in TTM ending quarter Jun 30 2022 and $ -3.51 millions for the twelve months ending in the quarter a year ago.

Longeveron Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
LGVN's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for LGVN's Competitors
Net Income Growth for Longeveron Inc 's Suppliers
Net Income Growth for LGVN's Customers

You may also want to know
LGVN's Annual Growth Rates LGVN's Profitability Ratios LGVN's Asset Turnover Ratio LGVN's Dividend Growth
LGVN's Roe LGVN's Valuation Ratios LGVN's Financial Strength Ratios LGVN's Dividend Payout Ratio
LGVN's Roa LGVN's Inventory Turnover Ratio LGVN's Growth Rates LGVN's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2022
Abbvie Inc 20.68%$ 20.676 millions
Utah Medical Products Inc19.76%$ 19.761 millions
Zynex inc 19.16%$ 19.160 millions
Avantor Inc 18.76%$ 18.758 millions
Chemed Corporation17.58%$ 17.575 millions
Maravai Lifesciences Holdings Inc 16.66%$ 16.656 millions
Mettler Toledo International Inc14.78%$ 14.779 millions
Ensign Group Inc14.27%$ 14.274 millions
Stryker Corp10.81%$ 10.811 millions
Zimmer Biomet Holdings Inc 8.07%$ 8.070 millions
Incyte Corporation8.01%$ 8.013 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CVU's Profile

Stock Price

CVU's Financials

Business Description

Fundamentals

Charts & Quotes

CVU's News

Suppliers

CVU's Competitors

Customers & Markets

Economic Indicators

CVU's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071